ENHANCED INTESTINAL ABSORPTION AND BIOAVAILABILITY VIA PRONIOSOMES FOR BAZEDOXIFENE ACETATE DRUG

SMITHA GANDRA*
*Department of Pharmaceutics, Marathwada Mitra Mandal’s College of Pharmacy, Thergaon, Pune, Maharashtra, India
Email: smithagandra@yahoo.com

Received: 29 Aug 2020, Revised and Accepted: 23 Oct 2020

ABSTRACT

Objective: The main objective of the present study was to develop proniosomal formulations to enhance the oral bioavailability of bazedoxifene acetate by improving solubility, dissolution and intestinal permeability.

Methods: Proniosomal powder formulations were prepared with bazedoxifene acetate drug varying the span 60 and cholesterol ratio in the range of 0.8:0.2 to 0.2:0.8 using maltodextrin as carrier by slurry method. The prepared proniosomal powder was filled into capsules. The bioavailability enhancement of proniosomes loaded with drug was studied focusing on non-ionic surfactants composition and drug: span 60 ratio. Prepared proniosomes were characterized for their particle size distribution, zeta potential, entrapment efficiency, in vitro dissolution study and thermal characteristics to understand the phase transition behavior. Further, the formulated proniosomes were subjected to stability behavior, ex vivo permeation studies using rat intestine followed by in vivo studies.

Results: Physico-chemical studies among various formulations helped in optimization of batch. Good flow properties confirmed from angle of repose values indicate easy filling into capsules. Enhancement in dissolution is due to incorporation of bazedoxifene acetate into the non-ionic surfactant and change in the physical state from crystalline to amorphous, thus improving oral bioavailability. Solid state characterization studies show the transformation to amorphous form with small particle size improving permeation. No drug excipient interaction was observed and sample is stable in refrigerated conditions. Ex vivo studies show significant permeation enhancement across gastrointestinal membrane compared to control. In vivo studies proved enhanced absorption of bazedoxifene acetate drug by oral route.

Conclusion: In conclusion, proniosomes provide a powerful and functional way of distribution of inadequately soluble bazedoxifene acetate drug which is proved from in vivo studies based on the enhanced oral delivery.

Keywords: Proniosomes, Niosomes, Permeability, Pharmacokinetics, Bioavailability

INTRODUCTION

The improvement of oral extent of absorption for poorly or inadequately aqueous soluble active pharmaceutical ingredient is still the most crucial and demanding feature in development of dosage forms. Curative success of a drug relies upon the extent and rate to which the drug is absorbed and thus upon the amount of solute that enters in a unit volume of solvent of drug molecule to show the pharmacological action. The premier method of evaluating therapeutic success of drugs with a low solubility is by checking bioavailability. The conventional techniques of improving the bioavailability act by enhancing the dissolution behaviour [1] such as reducing the particle size by co-grinding technique [2], solid dispersion [3], spherical agglomeration [4] but can't preclude or alter the gastrointestinal (GI) tract barrier function and presystemic metabolism. Along with above some more disadvantages add to the list such as particulate aggregates formation, toxicity from vehicles, relatively high cost of production, poor loading of drug, GI tract irritation caused from high concentration of excipients and low stability of developed dosage form [5, 6].

Hence to overcome all such difficulties encapsulation of the drug in vesicular structures [7] in the form of pharamacosomes, liposomes [8], niosomes [9], cubosomes, transferosomes are one such system, which can be expected to prolong the duration of the drug in systemic circulation, and reduce the toxicity by selective uptake along with lymphatic transport thus leading to improved permeation [10] along with rate and extent of absorption by avoidance of first pass metabolism [11]. However, they suffer from a number of important drawbacks that has prevented its widespread use. Niosomes [12] which are comparatively stable chemically and cheap in price because of usage of surfactants instead of phospholipids used in liposomes face physico-stability problems namely sedimentation of particles leading to fusion and aggregation and also leakage of drug upon storage.

In order to improve the stability of vesicular systems [13] and circumvent all of the complications, a modern contemporary technique to produce vesicular systems, provesicular systems was introduced without altering or affecting intrinsic properties of the drugs entrapped. Provesicular systems [14] namely proniosomes and proniosomes consist of phospho-lipids or non-ionic surfactants loaded with drug respectively along with readily aqueous soluble carrier that is coated with surfactant (non-ionic) to form dry, free flowing product. Thus, upon contact with sterilized water which helps in generation or emergence of niosomes from proniosomes eliminates many physical steadiness difficulties associated with niosome dispersions. With benefits of firmness during sterilization, measuring, transfer, distribution and storage proniosomes became a versatile system for delivery of numerous drugs [18, 19].

Bazedoxifene acetate, a novel third generation Selective Estrogen Receptor Modulator (SERM) is used in the prevention and treatment of postmenopausal osteoporosis [20]. An ideal SERM used for treatment of postmenopausal osteoporosis should avoid fractures controlling bone loss, decrease the risk of both cancers endometrial and breast. It should also provide comfort and calmness from symptoms associated with menopause without increasing the risk of thrombosis and coronary heart disease [21]. Bazedoxifene is processed to have beneficial effects on lipid and bone with minimum stimulation of breast or uterine tissues [22]. Bazedoxifene mechanism of action involves adhering to estrogen receptors (ER) in tissues of bone as agonist promoting bone mineral and density preservation [23]. In the similar manner, bazedoxifene acetate acts as antagonist, tissue in uterine and breast thus preventing
stimulation and proliferative action [24]. To the best of our knowledge, no articles are available in literature on proniosomes of bazedoxifene acetate and henceforth an attempt was made to focus on main objective of research work which is to formulate and evaluate and study the enhancement in intestinal absorption and bioavailability. Solid state characterization helps in investigating the morphology and physical state. Further ex-vivo and in vivo studies carried out to assess the permeation of drug from proniosomes using rat intestine and improvement in oral bioavailability from pharmacokinetic studies in rats respectively.

MATERIALS AND METHODS

Animal studies for both ex vivo and in vivo experiments was conducted at Albino research center (Registration No. 1722/RO/Ere/S13/CPCEA) with prior approval of institutional animal ethical committee. Euthanasia and disposal of carcass were in accordance with the guidelines.

Bazedoxifene acetate was a kind gift sample from MSN labs, Hyderabad, India. Span and Cholesterol (>99%) procured from Sigma, St. Louis, Missouri, United States of America. Maltodextrin was a generous gift sample from Dr. Reddy’s laboratories, Hyderabad. All other chemicals were of analytical grade and solvents were of HPLC grade. Freshly collected double distilled water was used all through the experiment.

Formulation of proniosomes

Essential components of proniosomes used in the formulation are non-ionic surfactants acting as permeability enhancers, carrier or coating material and membrane stabilizers. Among the carriers, maltodextrin and sorbitol are available in the preparation of proniosomes. Maltodextrin usage as carrier in preparation of proniosomes permits stretchability in the incorporation of surfactant and other ingredients at various ratios. Sorbitol usage results in formation of mass that is like solid cake [25]. Non-hygroscopicity and compatibility with drugs are added advantages with maltodextrin. Finally, efficient rehydration is the outcome when the surfactant is coated as thin coat which is made possible by maltodextrin because of its high surface area and preserved morphology [26].

The maximum benefit of proniosomal systems can be achieved when it forms stable niosomes with high entrapment efficiency after hydration in the gastric fluids. Cholesterol, structural lipid helps in accentuating the entrapment of drugs preventing it leakage by stabilizing the bilayered membrane. Though lecithin is other alternative for cholesterol as membrane stabilizer, lecithin is not widely used as it imparts lesser stability when measured against cholesterol [25].

Proniosomes were prepared varying the non-ionic surfactant and cholesterol ratios in the range of 0.8:0.2 to 0.2:0.8 using maltodextrin as carrier assigning the codes for various formulations. All surfactants used were in excess of their critical micelle concentrations. In the present invention among spraying method, coacervation phase separation method and slurry method for preparation of proniosomes; slurry technique or process [25] is adapted and the composition represented (table 1).

### Table 1: Composition for bazedoxifene acetate loaded proniosome powder using maltodextrin

| Formulation code | API (mg) | Maltodextrin (mg) | Molar ratio (SPAN 60: CHOL) | SPAN 60 (mg) | CHOL (mg) |
|-----------------|---------|------------------|----------------------------|-------------|----------|
| BPN1            | 10      | 250              | 0.8:0.2                    | 86.0        | 19.3     |
| BPN2            | 10      | 250              | 0.7:0.3                    | 75.3        | 28.9     |
| BPN3            | 10      | 250              | 0.6:0.4                    | 64.5        | 38.6     |
| BPN4            | 10      | 250              | 0.5:0.5                    | 53.8        | 48.2     |
| BPN5            | 10      | 250              | 0.4:0.6                    | 43.0        | 57.9     |
| BPN6            | 10      | 250              | 0.3:0.7                    | 32.3        | 67.5     |
| BPN7            | 10      | 250              | 0.2:0.8                    | 21.5        | 77.2     |

API—Bazedoxifene acetate drug, CHOL—Cholesterol

Evaluation/Characterization of proniosomes

Hydration of proniosomal systems

Hydration of Proniosomal systems is judged by studying the form, shape and structure of the niosomes formed from the proniosomes by optical microscopy (Olympus-CH20i). Procedure involves addition of small or little quantities of water onto a cavity glass slide where the proniosome powder was taken. Under an optical microscope the formation of niosomes was monitored and photomicrograph was taken.

Measurement of micromeritic properties of proniosomal systems

Micromeritic properties are assessed by flow properties of powder which are vital in handling and processing operations and for further dosage form development. Flow properties are reviewed from angle of repose [27] studied by fixed-funnel technique [28]. Briefly, proniosome powder was poured into a funnel which was fixed at a position so that the 13 mm outlet orifice of the funnel is 10 cm above a level black surface. The powder flowed down from the funnel to form a cone on the surface, and the angle of repose was measured where the proniosome powder was taken. Under an optical microscope the formation of niosomes was monitored and photomicrograph was taken.

### Determination of size of niosomes, zeta potential, entrapment efficiency and number of niosomes

For quantifying these parameters proniosome powders are to be converted into niosome dispersions, which are obtained by hydration followed by 3 min bath sonication (Soltect 2200MH, India). For the thus formed niosomes average size and its distribution is checked by Nano particle Analyzer (Horiba SZ-100, Japan). The principal behind which, is spectroscopic technique by photon correlation approach. Smoluchowski equation method is used to check zeta potential [30].

\[
\zeta = \frac{UE\eta}{\varepsilon}
\]

Where, \(\zeta\) is zeta potential, \(UE\) is electrophoretic mobility, \(\eta\) is viscosity of the medium, and \(\varepsilon\) is dielectric constant.

After suitable dilution of proniosomes with freshly collected double distilled water, the samples are proceeded for further analysis. Niosome size and Polydispersity Index (PI) of formed niosomes were obtained directly from the Nano particle Analyzer and ZetaSizer equipment and entrapment efficiency from earlier mentioned and reported ultra-filtration technique which was carried out using Centrirsart (Sartorius AG Gottingen, Germany) equipment [31]. % Entrapment efficiency is obtained by subtracting unentrapped drug from total amount of drug.

Provesicular formulations are optimized based on the number of vesicles formed after the hydration. The niosomes formed after hydration of proniosome powder were counted by optical microscope (Olympus CH20i, India) using a hemocytometer, and the number of niosomes per cubic mm was calculated by using the following formula [31].

\[
\text{Total number of niosomes per mm}^3 = \frac{\text{Total number of niosomes counted} \times \text{dilution factor} \times 4000}{\text{Total number squares counted}}
\]
In vitro dissolution study

In vitro dissolution studies (Lab India DS 0000, India) for proniosome powders (filled in capsule dosage form) compared against control (filled in capsule dosage form) are performed in USP type-I (basket) apparatus containing 900 ml of dissolution medium (pH 1.2 simulated gastric fluid) kept at a controlled temperature of 37±0.5 °C for which the basket speed is set at 50 rpm. 5 ml sample was removed maintaining the sink conditions at definite time points, filtered through 0.45 μm millipore membrane filter prior to analysis and drug release was analyzed by UV Visible Spectrophotometer (Lab India UV 3000+, India), determining the absorbance at 299 nm for bazedoxifene acetate [32].

Scanning electron microscopy (SEM)

By SEM (Hitachi S-3700N, Japan) technique morphology of surface for both the pure drugs, and developed optimized proniosomes was identified [33]. Scanning electron microscopic images or pictures are taken at an accelerating voltage of 15 keV. Upon brass stub samples are made to adhere with the help of adhesive tape (double sided), followed by slider layer gold coating upon sample makes it electrically conductive which is prerequisite for observing and taking images.

Transmission electron microscopy (TEM)

TEM (JEOL-100CX-II, Tokyo, Japan) technique also helps in knowing the form, shape and structure of samples as in SEM but in more detail. Prior to observation of samples, upon a copper grid (coated with carbon) sample lean film is to be negatively stained using 0.2 % w/v solution of sodium phosphotungstate left for air drying followed by imaging [34].

Differential scanning calorimetry (DSC)

DSC (Shimadzu 60H, Tokyo) analysis of optimized formulation and pure drug are studied for the molecular state of the compound. DSC curves help in deducing heat of fusion and melting point. Approximately 5±2 mg of sample is taken in a sealed pan (hermetically) made of aluminum and gradually exposed to temperature at 10 °C min⁻¹ heating rates from 20 °C-300 °C under gas (N₂) flow at a constant rate of 30 ml min⁻¹.

Powder X-ray diffractometry (PXRD)

The PXRD (Shimadzu 7000, Tokyo) repeated format for both drugs and most effective powder formulations are received at a voltage of 45 kilovolts; when a beam of Cu Kα radiation, generated from 40 mA current moves forward through Ni filtered monochromator made up of graphite onto detector. All samples were run at 1° (2θ) min⁻¹ from 3° to 45° (2θ).

Fourier transform infrared spectroscopy (FT-IR)

IR spectra of drug, best powder formulation and excipients such as maltodextrin are acquired from FT-IR spectrophotometer (Shimadzu 8400S, Japan) at a scanning range of 4000 –400 cm⁻¹ with 10 AT solvent delivery unit. A C8 reverse phase stainless steel analytical column (150×4.6 mm) with 5 μm particle size was employed for chromatographic separation (Hyperisor BDS). The column eluent was monitored at a wavelength of 299 nm using a PDA detector, and the sensitivity was set at 0.005 AUFS at ambient temperature. The serum samples were processed by protein precipitation method. Briefly, 100 μl of serum sample was treated with 100 μl of internal standard (1 μg/ml of raloxifene hydrochloride in methanol) and vortexed (Remi Equipments, India) for 1 min. The drug was extracted with 0.2 ml of acetonitrile, vortexed for 10 min followed by centrifugation at 4000 rpm for 15 min and the separated organic layer was injected onto the HPLC (20 μl). The limit of detection and quantification were 10 and 30 ng/ml, respectively. The concentration vs. peak area ratio plot was linear (r²>0.99) over the concentration range of interest (standard preparation) and the bazedoxifene acetate content in samples was quantified using this plot.

Stability studies

Stability for the best formulations is studied for a period of 180 d for various parameters such as particle size of niosomes formed from proniosome, percentage retention of drug and ex vivo permeation across rat intestine. At predetermined time points that is 0,30,60,90,120 and 180 d samples kept at 24±2 °C and 4±2 °C in aluminum foil covered glass vials are taken out hydrated, looked for crystal formation of drug under microscope (optical) and also for above mentioned parameters.

Ex vivo absorption study using rat intestine

Albino wistar rats (male) approximately weighing 200 gm are selected for these investigations which are fasted for overnight. These wistar rats are split up into 2 groups with 6 in every group and delivered with each treatment at a random basis. Two group includes one for control (pure drug–oral suspension) and one for optimized proniosome formulation. Accurately weighed dose of 10 mg per kg body weight the drug or optimized formulation are administered. 250 μl of blood sample is taken or withdrawn into micro centrifuge tubes retro orbital plexus at definite time points. Serum was obtained from the collected blood which was left to clot by centrifugation process for 10 min at 10 000 rpm using centrifuge (Remi R-24, India). Thus, obtained drug containing serum is stored at a temperature of 20 °C until further analysis.

Calculation of pharmacokinetic parameters

Cmax and Tmax are picked up from the graph plotted between concentrations of drug in serum at various time points. Trapezoidal rule technique is followed to determine AUC∞. In the same way AUC∞ was calculated by dividing concentration of drug at last time point in the serum with Kₚ. The relative bioavailability was estimated by dividing the AUC∞ of proniosome formulation with control oral suspension.
Statistical analysis
The data obtained were subjected to student’s ‘t’ test and one-way analysis of variance (ANOVA), and the significance of difference between formulations was calculated by student-Newman–Keuls (compare all pairs) with Instat Graphpad prism software (version 4.00; GraphPad Software, San Diego California). The level of statistical significance was chosen as p<0.05.

Ex-vivo/In vivo correlation
Ex-vivo/In vivo Correlation was performed by determining the r² value from the graph plotted between the AUC of In vivo and ex vivo concentration at different time points [37].

RESULTS AND DISCUSSION
Preparation of proniosome powders
In the present study proniosomes are formulated, developed and assessed for their scope in raising the quality of the delivery of bazedoxifene acetate drugs by oral route. Accurately weighed amounts using weighing balance (sartorius TE 124S, Germany) for mixture (250 µM) containing different types of spans and cholesterol at diversified molar ratios (0.8:0.2, 0.7:0.3, 0.6:0.4, 0.5:0.5, 0.4:0.6, 0.3:0.7, 0.2:0.8) and active component or ingredient (10 mg) were solubilized in 20 ml of chloroform and methanol (2:1). The formed mixture was shifted into 250 ml flask with round bottom and upon addition of maltodextrin (250 mg) slurry was formed. The round bottomed flask was connected to a rotary vacuum evaporator (Rotavap PBU-6, India) to remove organic solvent by evaporation process at low pressure and 45±2 °C temperature with 60 to 70 rpm. Complete removal of organic solvent, results in dry product and leaving it in a vacuum oven at 24 °C for a night further makes the product free flowing. Thus, acquired proniosome powders are kept in glass vial at 4 °C which can be delivered in the form of capsules. For comparison, control formulation devoid of spans and cholesterol was processed.

Niosomes are formed from proniosomes immediately upon contact with water at in vitro conditions or with body fluids at in vivo conditions which is considered to be achieved without great effort when compared with traditional technique of preparation of niosomes by dry-film procedure as plan of work involves tedious shaking process to absorb water by surfactants. Thus, the production from proniosomes is considered as the greatest advantage i.e., eases of use.

Evaluation/characterization of proniosomes
Evaluation of proniosomes after preparation aids in characterizing the formulation and identifying the optimized formulation [38-40].

Hydration of proniosome systems
Upon hydration of proniosomes, niosomes were derived and are formed immediately upon contact with water and the photomicrographic images at different magnifications are represented (fig. 1).

Measurement of micromeritic properties of proniosome systems
The measurement of flow properties of the proniosome powders plays key role as its values helps in various operations during manufacturing of a dosage form such as ease with which the powders are filled into the container and uniformity of the dose.

Angle of repose, Carr’s compressibility index and Hausner’s ratio results help in evaluating flow measurements. Cohesion or Internal friction between the particles is dependent on the angle of repose values which are directly proportional to each other. Therefore, smaller the angle of repose values (23 °) better will be the flow properties. This is strengthened by Carr’s compressibility index values which are less than 13 and Hausner’s ratio which are less than 1.20 [27] and the results are indicated (table 2). Out of all formulations BPN3 is having excellent flow property considering angle of repose.

| Formulation code | Angle of repose* | Compressibility index* | Hausner’s ratio* |
|------------------|------------------|------------------------|------------------|
| BPN1             | 22.85±0.18       | 12.62±0.23             | 1.19±0.15        |
| BPN2             | 22.76±0.20       | 13.61±0.15             | 1.23±0.19        |
| BPN3             | 23.48±0.23       | 13.76±0.12             | 1.28±0.14        |
| BPN4             | 21.29±0.16       | 11.85±0.08             | 1.05±0.17        |
| BPN5             | 21.60±0.14       | 12.90±0.06             | 1.20±0.23        |
| BPN6             | 21.25±0.17       | 12.84±0.08             | 1.26±0.22        |
| BPN7             | 23.13±0.32       | 12.89±0.13             | 1.14±0.26        |

*Average of three determinations±Standard deviation
Determination of size of niosomes, zeta potential, entrapment efficiency and number of niosomes

Determination of size of the niosomes and size distribution of niosomes formed is significant [41]. The average niosome size was in between 189–243 nm. Concentration of the cholesterol and length of the surfactant alkyl chain influences the size of the niosomes. Longer the chain length smaller the size of niosomes.

The particle size increased because of increase in the width of lipid bilayers, when cholesterol concentration increases to have positive effect on the bilayer characteristics such as rigidity and hydrophobicity.

The polydispersity index values are inside the allowable limits for all the proniosomal formulations, indicating enhanced homogeneity which is to judge unimodal size distribution. The lower the polydispersity index value, the more monodispersed the dispersion which is less than 0.3 for all the proniosomal formulations.

A zeta potential value for all proniosomal formulations was between 50.6 and 55.5 mV.

Ultra-filtration procedure is employed to determine the amount of drug entrapped as the procedure doesn't involve any dilution levels which is less than 0.3 for all the proniosomal formulations. Among various formulations, the formulation with following code BPN4 showed relatively low drug encapsulation against prepared using Span 60 which is due to insufficient amount of cholesterol that is niosomes are obtained only when the cholesterol content is above 33.33 mol%. Amount of cholesterol directly influences the encapsulation of the drug with reverse action on niosome size.

The more the number of niosomes from proniosomes in the GI tract upon hydration, the better the dosage form can be speculated. Among various formulations, the formulation with following code BPN4 demonstrate good number of niosomes. The results of all above mentioned physico-chemical parameters are represented (table 3) for various proniosomal formulations.

Table 3: Physico-chemical characterization of various pronioscular systems of bazedoxifene acetate

| Formulation code | Particle size \(\mu m\) | Polydispersity Index | Zeta potential* | % Drug entrapped\(\%\) | Number of vesicles/mm\(^3\) x 10\(^3\) |
|------------------|---------------------------|----------------------|-----------------|----------------------|-----------------------------|
| BPN1             | 232±14                    | 0.239                | 53.6±2.0        | 83.5±2.5             | 3.49                        |
| BPN2             | 222±17                    | 0.154                | 54.1±3.4        | 81.7±1.9             | 4.03                        |
| BPN3             | 209±23                    | 0.200                | 50.6±1.6        | 84.6±1.8             | 3.88                        |
| BPN4             | 189±21                    | 0.287                | 55.5±2.9        | 89.9±2.4             | 4.50                        |
| BPN5             | 199±12                    | 0.178                | 54.3±3.6        | 81.0±2.7             | 3.67                        |
| BPN6             | 228±09                    | 0.32                 | 51.7±1.9        | 80.4±3.2             | 3.59                        |
| BPN7             | 243±27                    | 0.287                | 52.3±2.8        | 76.5±3.6             | 3.42                        |

*Average of three determinations±standard deviation

In vitro dissolution study

The percent drug release was outstandingly more for almost all proniosomal powder formulations when measured against control in the respective dissolution medium. The amount of bazedoxifene acetate released from proniosomes was ranging between 70 % and 96 % in 30 min and was remarkably higher compared to control which is 8 % for same time period as shown (fig. 2) and the results are represented (table 4).

Dissolution efficiency of drugs has drastically increased when the drug is delivered in the form of proniosome systems, which might be attributed to the improved solubility of drug by non-ionic surfactant molecules or transformation of the crystalline state of the drug to amorphous state [44].

Scanning electron microscopy

Scanning electron microscopy images (fig. 3) aids in studying the surface morphology of the proniosome powders along with drug and carriers. Non-existence of drug crystalline structure in proniosomes is specified the conversion of drug to molecular or amorphous state from crystalline form. And also, maltodextrin porous structure was not visible in formulations because of settling of spans on the surface of carrier.

Table 4: Dissolution data of bazedoxifene acetate in pure form and various proniosomal formulations using span 60

| Time (min) | Cumulative percent drug released*±SD |
|-----------|-------------------------------------|
| 0         | Control: 0.00±0.00, BPN1: 0.00±0.00, BPN2: 0.00±0.00, BPN3: 0.00±0.00, BPN4: 0.00±0.00, BPN5: 0.00±0.00, BPN6: 0.00±0.00, BPN7: 0.00±0.00 |
| 5         | 4.25±0.44, BPN1: 43.00±6.54, BPN2: 45.75±0.81, BPN3: 47.00±0.45, BPN4: 60.00±0.57, BPN5: 53.25±0.39, BPN6: 41.50±0.26, BPN7: 41.00±0.57 |
| 10        | 6.27±0.31, BPN1: 57.84±6.06, BPN2: 62.50±0.71, BPN3: 66.26±0.68, BPN4: 77.83±0.21, BPN5: 62.30±0.60, BPN6: 51.73±0.20, BPN7: 53.23±0.39 |
| 30        | 8.06±0.29, BPN1: 85.06±0.37, BPN2: 82.85±0.21, BPN3: 88.38±0.97, BPN4: 96.01±0.32, BPN5: 85.64±0.48, BPN6: 73.02±0.21, BPN7: 70.27±0.79 |
| 60        | 12.10±0.57, BPN1: 91.03±0.42, BPN2: 92.31±0.90, BPN3: 93.62±0.84, BPN4: 97.29±0.81, BPN5: 94.11±0.55, BPN6: 82.42±0.57, BPN7: 80.66±0.49 |
| 90        | 16.17±0.64, BPN1: 93.53±0.78, BPN2: 94.52±0.64, BPN3: 94.63±0.33, BPN4: 98.50±0.44, BPN5: 97.31±0.85, BPN6: 80.62±0.67, BPN7: 88.85±0.11 |
| 120       | 20.01±0.18, BPN1: 98.04±0.91, BPN2: 98.58±0.57, BPN3: 98.90±0.66, BPN4: 100.86±0.89, BPN5: 97.11±0.29, BPN6: 98.34±0.70, BPN7: 99.12±0.10 |

*Average of three determinations±standard deviation
FIG. 2: Cumulative percent drug release versus time plots of bazedoxifene acetate in pure form and proniosomal formulations using span 60

![Graph showing cumulative percent drug release versus time plots for different formulations.](image)

**Fig. 2:** Cumulative percent drug release versus time plots of bazedoxifene acetate in pure form and proniosomal formulations using span 60.

**Fig. 3:** SEM Images of (a) Bazedoxifene acetate (b) Proniosome powder (c) Maltodextrin

Transmission electron microscopy

Transmission electron microscopy is a microscopic technique commonly used for the analysis of materials on the nanoscale. Because it uses electrons, which have a shorter wavelength than light, it is capable of achieving resolution a thousand times better than that can be achieved with a light microscope [45].

Transmission Electron Microscopy analysis confirms the spherical shape of niosomes formed after hydration of proniosomal systems (fig. 4). The image analysis showed that the niosomes was surrounded by homogeneous shading, this suggests that formed niosomes resembled the drug-enriched core model.

Differential scanning calorimetry

In differential scanning calorimetry thermograph of proniosome formulations, endotherm peak fades away or vanishes around melting point which is clearly visible in pure drug differential scanning calorimetry thermograph indicating the metamorphosis of crystalline state in pure drug to amorphous state in formulations (fig. 5a and 5b).

Powder X-RAY diffractometry

Reduction in the intensity or absence of characteristic drug peaks in the proniosome optimized formulations compared to pure drug bazedoxifene acetate further confirms the amorphization of the drug by PXRD analysis (fig. 6a and 6b).

![TEM Images of bazedoxifene acetate proniosome powder](image)

**Fig. 4:** TEM images of bazedoxifene acetate proniosome powder
Fig. 5a: DSC of bazedoxifene acetate

Fig. 5b: DSC of optimised formulation of BPN

Fig. 6a: PXRD of bazedoxifene acetate

Fig. 6b: PXRD of optimised formulation of BPN
FT-IR analysis

FT-IR spectrum of proniosomal formulation without any extra peaks when compared to pure drug spectrum extrapolates the lack of chemical interaction as indicated (fig. 7a, 7b, 7c).

Based on the various evaluation parameter results the optimized formulation further proceeded for stability, ex vivo and in vivo studies.

Stability studies

Shelf life for drug under stated conditions is dictated by the amount of drug retained within the niosomes. Physical appearance, size of the niosomes, percentage retention and ex-vivo permeation across rat intestine of respective drug after storing at 24 °C and 4 °C temperature for 6 mo are investigated in the stability studies for optimized formulation. Samples were pulled out at specified time points and proniosomal powders were restored to form niosomal dispersions. Initially the powder was found to be dry, free flowing in nature without any lumps, after contact with water lead to the formation of niosomes immediately. Under optical microscope drug crystallization was also not observed. No change in the size of the particles and size distribution represents proniosomal formulation stability. Significantly more amount of drug retention was observed at all sampling points. And also, ex-vivo permeation study results indicated not much variation in amount of drug permeated, flux, permeability co-efficient and enhancement ratio values when compared to initial. In contrast, the formulation was destabilized at room temperature (24 °C) resulting in larger niosome size, drug leakage with less entrapment efficiency with time and chaotic ex-vivo permeation results.

The stability studies as represented (table 5) suggest that the proniosomal powder was comparatively more stable when stored at refrigerated conditions (4 °C) that at room temperature (24 °C).

Fig. 7a: IR spectrum of bazedoxifene acetate

Fig. 7b: IR spectrum of BPN4 formulation
**Ex vivo absorption study using rat intestine**

Permeation across the gastrointestinal tract is also a rate limiting step for absorption of drug other than dissolution. Therefore, *ex vivo* permeation studies were performed using the rat intestine. Since a great number of available active pharmaceutical ingredients get absorbed *in vivo* from the small intestine it is more relevant to use the rat tissue [46]. Hence, we have used ileum portion to evaluate the potential of proniosome powder formulations for increasing the permeation of drug across the intestine barrier.

The amount of drug permeated from proniosomal systems for bazedoxifene acetate has enhanced when compared with respective control within a period of 2 h as shown in graphical image (fig. 8). The flux values also improved for proniosomal system when compared with control. The ER above 1 shows enhanced permeation of proniosome when compared with control.

Thus, the remarkable improvement in the permeation can be owed to the combination of several mechanisms such as presence of nonionic surfactant which could obviate the barrier function due to the fluidization of the intercellular lipid bilayer, better membrane contact and permeation enhancement property of the non-ionic surfactants might have led to altered permeability characteristics of the membrane which otherwise result in improved partitioning of the drug into the bilayer and also direct transfer of niosomes across the epithelial membrane.

**In vivo bioavailability study**

**Pharmacokinetic study**

The average serum concentration vs time intervals after orally administering optimized formulation of bazedoxifene acetate proniosome powder in comparison against control (pure drug at a dose of 10 mg/kg) are shown. Various pharmacokinetic parameters are calculated and represented (table 6). Results obtained show a higher Cmax and Tmax for proniosomes when compared against control. Slower excretion of bazedoxifene acetate drug from proniosomes is evidently the reason for higher mean residence time (MRT) when compared against control. Area under the Curve (AUC) values following oral administration is remarkably more when compared against control, indicating higher systemic exposure thus overcoming the bioavailability problem; which is raised as a result of increased hepatic metabolism. Relative bioavailability for drug after giving proniosomes by oral route was found to be more when compared against control with a significant difference of p<0.001. Thus, it is proved from the reports that bioavailability of bazedoxifene acetate have been markedly improved from proniosomal systems when compared against control. The permeability and potential uptake of slightly soluble drugs is increased, thus enhancing the bioavailability. Overall improvement in the relative bioavailability (RA) deduces the potential of proniosomes as a suitable carrier for improved oral delivery of bazedoxifene acetate.

**Ex vivo/In vivo correlation**

The R² values are closer to linear for optimized formulation of drug when graph is plotted between the AUC of *In vivo* and *Ex vivo* concentration at different time points, thus concluding a correlation as shown (fig. 9).

---

**Table 5: Stability study data for optimized formulation (BPN₁)**

| Stability evaluation parameters | Initial  | 30d    | 60d    | 90d    | 120d   | 180d   |
|--------------------------------|----------|--------|--------|--------|--------|--------|
| Particle Size                  | 189±21   | 185±11 | 184±13 | 187±15 | 186±20 | 188±13 |
| %Retention of drug             | 89.9±2.4 | 88.0±2.6| 86.0±2.9| 89.0±3.4| 88.6±2.5| 90.0±2.2|
| Cumulative amount drug permeated (µg/cm²) | 227.6±31 | 223.5±18| 219.4±21| 228.1±20| 223.6±23| 209.9±32|

*Average of three determinations±Standard Deviation*
Table 6: Pharmacokinetic parameters of bazedoxifene acetate in rats following oral administration of optimized formulation (mean±standard deviation, n=6)

| Pharmacokinetic parameters | Control            | BPN4            |
|----------------------------|--------------------|-----------------|
| Cmax (µg/ml)               | 0.639±0.02         | 0.974±0.012     |
| Tmax (h)                   | 2.0±0.00           | 2.0±0.00        |
| T1/2 (h)                   | 31.735±0.663       | 27.494±0.6      |
| Ke (h⁻¹)                   | 0.022±0.605        | 0.025±0.001     |
| AUC₀⁻₅ (µg. h. ml⁻¹)      | 17.011±0.264       | 23.745±0.5      |
| AUC₀⁻∞ (µg. h. ml⁻¹)      | 19.346±0.242       | 26.870±0.7      |
| MRT₀⁻∞ (h)                | 17.475±0.194       | 20.06±0.38      |
| RA                         | 1.39±0.05          |                 |

CONCLUSION

Bazedoxifene acetate proniosomes were prepared by slurry method using maltodextrin as carrier at varying ratios of spans and cholesterol. The formulation containing 0.5:0.5 of span 60 and cholesterol was optimized based on the physicochemical characterization and dissolution studies. The in vivo pharmacokinetic studies reveal potential of proniosomes as suitable carriers for poorly soluble drug. The results of this study clearly indicate the improvement in intestinal absorption and oral bioavailability of bazedoxifene acetate. The improved delivery of niosome entrapped drug is mediated by vesicle adsorption onto the cell surface followed by endocytosis. A particularly attractive feature of this study is that it may be applied to preparations for oral administration, a proniosome composition may be placed inside a capsule which is then swallowed whole. Depending on the design of the capsule, the contents will be released somewhere in the gastrointestinal tract to form niosomes in vivo. The drug remains protected within the layers of the niosomes. It has been suggested that protecting a poorly absorbed, labile drug in this manner could help absorption. In this connection, it has been noted that niosomes can form, irrespective of the ionic strength of the aqueous environment, in the range pH 3.2 to 8.6. It is assumed that any "free" drug remaining in the aqueous environment after spontaneous niosome formation is non-toxic and need not be removed. A further in vivo study in humans fortifies the improved oral delivery of bazedoxifene acetate prior to human use.

ACKNOWLEDGEMENT

The authors are grateful to MSN labs, Hyderabad for providing the gift sample of bazedoxifene acetate. The authors are thankful to
Lipoid, Germany for the generous gift of Phospholipon 90H. The authors acknowledge Management, Principal of Sri Venkateshwara college of Pharmacy, Surabhi educational society for providing the necessary facilities to carry out the work.

AUTHORS CONTRIBUTIONS
The author smitha gandra has performed the experimental work and calculations along with drafting of paper.

CONFLICT OF INTERESTS
The authors report no conflicts of interest.

FUNDING
This work is completely self-funded.

REFERENCES
1. Swati S, George M, Lincy J. Improvement in solubility of poor water-soluble drugs by solid dispersion. Int J Pharm Investig 2012;2:12-7.
2. Smitha G, Areefulla SH, Swamy PV. Enhancement of in vitro dissolution characteristics of nifedipine by co-grinding technique. Int J Pharm Chem Sci 2012;1:279-85.
3. Amrin S, Prashant B, Reeshwa N. Solubility enhancement of celecoxib by solid dispersion technique and incorporation into topical gel. Asian J Pharm Clin Res 2019;12:294-300.
4. Parmar SS, Mishra R, Shirodkar S. Spherical agglomeration a novel approach for solubility and dissolution enhancement of simvastatin. Asian J Pharm Clin Res 2011;4:95-72.
5. O’Driscoll CM, Griffin RT. Biopharmaceutical challenges associated with drugs with low aqueous solubility—the potential impact of lipid-based for formulations. Adv Drug Delivery Rev 2008;60:617–24.
6. Tang B, Cheng G, Gu JC, Xu CH. Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discovery Today 2008;13:606–12.
7. Jha AK, Kumar R, Kumar S, Jha SS. Vesicular system carrier for drug delivery. Pharm Sin 2011;1:192-202.
8. Schreier H, Bouwstra J. Lipoosomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Controlled Release 1994;30:1-15.
9. Ijomma FU, Vyaz SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998;172:33-70.
10. Deepthi Annakula, Madhukar Rao Errabelli, Raju Jukanti, Suresh Bandari, Prabhakar Reddy Veerareddy. Provesicular drug delivery systems: an overview and appraisal. Arch Appl Pharm Sci Res 2010;2:35-46.
11. Sarala Y, Natarajan V, Veevan GK, Zhijun W, Manish I, Guru RV. Proliposomes as a drug delivery system to decrease the hepatic first-pass metabolism: case study using a model drug. Eur J Pharm Sci 2014;64:26-36.
12. Yasam VR, Jakki SL, Natarajan J, Kuppusamy G. A review on novel vesicular drug delivery: proniosomes. Drug Delivery 2014;21:243-9.
13. Gangadharapra HV, Gangadhvar B, Nagashubha B. Approaches for improvement of vesicular system-pro-vesicular drug delivery. Am J Pharm Tech Res 2014;4:1-67.
14. Bayindir ZS, Yuksel N. Provesicles as novel drug delivery systems. Curr Pharm Biotechnol 2015;16:344-64.
15. Hu C, Rhodes DG. Proniosomes: a novel drug carrier preparation. Int J Pharm 1999;185:23-35.
16. Garna PK, Pogaku R. Nonionic surfactant vesicular systems for effective drug delivery-an overview. Acta Pharm Sin B 2011;1:288-19.
17. Abd Elbary A, El-halify HM, Tadros ML. Sucrose stearate-based proniosome-derived niosomes for the nebulizable delivery of cromolyn sodium. Int J Pharm 2008;357:189–98.
18. Sankar V, Ruckmani K, Durga S, Juliani S. Proniosomes as drug carriers. Pak J Pharm Sci 2010;23:103-7.
19. Akhilesh D, Hazel G, Kamath JV. Proniosomes—a propitious vesicular drug carrier. Int J Pharm 2011;1:98-103.
20. Jaime Kulak Junior, Carolina Aguilar Moreira Kulak, Hugh S Taylor. SERMs in the prevention and treatment of postmenopausal osteoporosis: an update. Arq Bras Endocrinol Metabol 2010;54:200–5.
21. Hadji P. The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric 2012;15:513–23.
22. Chines AA, Komrn B. Bazedoxifene acetate: a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Drugs Today (Barc) 2009;45:507-20.
23. Diana M, Stefanie CN. Bazedoxifene: an investigational selective estrogen receptor modulator for the treatment and prevention of osteoporosis in postmenopausal women. Formulary 2011;46:159-76.
24. Ronkin S, Northington R, Baracet E, Nunes MG, Archer DF, Constantine G, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397–404.
25. Nagasamy Venkatesh D, Swetha Priyanka V, Tulasi K, Kalyani K, Sheik Abid Ali, Harikrishna J. Proniosomes: a superior drug delivery system. Int J Pharm Sci Drug Res 2014;6:178-82.
26. Bangham AD, Standish MM, Watkins JC. Diffusion of unsaturated ions across the lamellae of swollen phospholipids. J Mol Biol 1965;13:238-52.
27. Stanforth J. Powder flow. In: M Aulton. ed. Pharmaceutics, the science of dosage form design. 2nd ed. Churchill Livingstone: Longman Group Edinburgh; 2002. p. 197–210.
28. Lieberman HA, Lachman L, Schwartz JB. Pharmaceutical dosage forms: tablets, Marcel Dekker, New York; 1990. p. 201-43.
29. Curr RL. Evaluation flow properties of solids. Chem Eng 1965;72:163-8.
30. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Controlled Release 2005;107:215–28.
31. Jukanti R, Sheela S, Bandari S, Veerareddy PR. Enhanced bioavailability of exemestane via proliposomes based transdermal delivery. J Pharm Sci 2011;100:3208-22.
32. Smitha G. Determination of bazedoxifene acetate in bulk with the aid of UV-spectroscopy: development and validation. Int J Pharm Tech Res 2014;7:61-7.
33. Blazek Welsh AL, Rhee DG. SEM imaging predicts quality of niosomes from maldextrin-based proniosomes. Pharm Res 2001;18:656-61.
34. Mohamed S El-Ridy, Alia A Badawi, Marwa M Safar, Amira M Mohsen. Niosomes as a novel pharmaceutical formulation encapsulating the hepatoprotective drug silymarin. Int J Pharm Pharm Sci 2012;4:549-59.
35. Pradip KG, Rita JM, Manish LU, Rayasa SRM. Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. AAPS PharmSciTech 2006;7:E1-85.
36. Gandra S, Sheelam SCR, Maddela R, Reddymalla P, Bakshi V, Jukanti R. Bazedoxifene acetate quantification in rat serum with the aid of RP-HPLC: method development and validation. World J Pharm Sc 2015;3:2537-65.
37. Nel I, Gauler TC, Eberhardt WE, Nickel AG, Schuler M, Thomale et al. Endometrial effects of bazedoxifene et al. at. Bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Drugs Today (Barc) 2013;3:1223–9.
38. Almira I Blamek Welsh, David G. Rhodes. Maltodextrin–based proniosomes. Pharm Sc 2001;3:1-8.
39. Gupta A, Prajapati SK, Singh M, Balamurugan M. Proniosomal powder of captopril: formulation and evaluation. Mol Pharm 2007;4:596-9.
40. Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level box- Behnken design. Int J Pharm Pharm Sci 2015;9:130-37.
41. Nanemoo A, Jain NK. Niosomal delivery of 5-fluorouracil. J Microencapsul 1999;16:731-40.
42. Uchegbu IF, Florence AT. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Coll Interf Sci 1995;58:1-35.
44. Praveen SH, Kumaresh SS, Guru VB. Proliposomes of exemestane for improved oral delivery: Formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine. Int J Pharm 2009;380:96-104.

45. Bradbury S, Joy DC, Ford BJ. Transmission electron microscope (TEM). Encyclopedia Britannica; 2011.

46. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 2004;278:119-31.